Trial of ispinesib and docetaxel in cancer patients
Author Information
Author(s): Blagden S P, Molife L R, Seebaran A, Payne M, Reid A H M, Protheroe A S, Vasist L S, Williams D D, Bowen C, Kathman S J, Hodge J P, Dar M M, de Bono J S, Middleton M R
Primary Institution: Royal Marsden Hospital and Institute of Cancer Research
Hypothesis
The study aims to define the maximum tolerated dose (MTD), safety, pharmacokinetics, and efficacy of ispinesib in combination with docetaxel.
Conclusion
The study found that the combination of ispinesib and docetaxel can be safely administered, with the MTD defined as ispinesib 10 mg/m² and docetaxel 60 mg/m².
Supporting Evidence
- The MTD was ispinesib 10 mg/m² with docetaxel 60 mg/m².
- Twenty-four patients were treated at four dose levels.
- Prolonged neutropaenia was dose limiting in six patients.
Takeaway
Doctors tested a new cancer treatment combining two drugs, and they found a safe dose that doesn't cause too many side effects.
Methodology
Patients with advanced solid tumors were treated with ispinesib and docetaxel, with dose escalation to determine the MTD and assess safety and efficacy.
Limitations
The study had a small sample size and was limited to specific types of cancer.
Participant Demographics
{"median_age":61.2,"gender_distribution":{"male":21,"female":3},"tumor_types":{"hormone_refractory_prostate_cancer":14,"duodenal_adenocarcinoma":2,"cervical_cancer":2,"bladder_cancer":1,"renal_cancer":2,"colon_cancer":1,"melanoma":1,"esophageal_cancer":1}}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website